Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Medical Oncology
Published in: Medical Oncology 4/2012

01-12-2012 | Original Paper

Reciprocal expression of survivin and SMAC/DIABLO in primary breast cancer

Authors: A. Mansour, M. Nabil, R. Ali-Labib, H. Said, F. Annos

Published in: Medical Oncology | Issue 4/2012

Login to get access

Abstract

There is an intimate relation between disturbance in survivin and SMAC/DIABLO expressions and cancer formation in many tissues; however, this was not confirmed in the primary breast cancer. The aim of this study was to evaluate the relationship between survivin and SMAC/DIABLO mRNA expressions in primary breast cancer using RT-PCR and their relationship to some of the risk factors (age, family history, breast-feeding, use of contraceptive pills and hormonal receptors). Breast cancer tissues were studied for the detection of the mRNA expression of survivin and SMAC/DIABLO. This was done by qualitative reverse transcription–polymerase chain reaction (RT-PCR). SMAC/DIABLO mRNA was detected by RT-PCR only in 1 sample in breast cancer tissues (6.25%). However, it was expressed in 16 out of 25 (64%) of the benign tumor tissues (P = 0.00). In contrast, survivin mRNA was highly expressed in breast cancer tissues, 36 out of 48 (75%) (P = 0.00), while its expression was very low in benign tumor tissues, only 1 out of 37 (2.7%) (P = 0.00). Expressions of SMAC/DIABLO and survivin were significantly reciprocal in breast cancer and benign tumor tissues. SMAC/DIABLO inhibits apoptosis of breast cancer cells by suppression of survivin. These two genes probably form an important link in the signaling pathway of formation of breast cancer cells, which may be chosen as therapeutic targets in the primary breast cancer.
Literature
1.
2.
Abbas H, Elyamany A, Salem M, Salem A, Binzaid S, Gamal B. The optimal sequence of radiotherapy and chemotherapy in adjuvant treatment of breast cancer. Int Arch Med. 2011;4(1):35.PubMedCrossRef
3.
Rusiecki JA, Holford TR, Zahm SH, Zheng T. Breast cancer risk factors according to joint estrogen receptor and progesterone receptor status. Cancer Detect Prev. 2005;29:419–26.PubMedCrossRef
4.
5.
6.
Song Z, Yao X, Wu M. Direct interaction between Survivin and SMAC/DIABLO is essential for the anti-apoptotic activity of Survivin during taxol-induced apoptosis. J Biol Chem. 2003;278:23130–40.PubMedCrossRef
7.
8.
Du C, Fang M, Li Y, Li L, Wang X. SMAC, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell. 2000;102:33–42.PubMedCrossRef
9.
Adrain C, Creagh EM, Martin SJ. Apoptosis-associated release of SMAC/DIABLO from mitochondria requires active caspases and is blocked by Bcl-2. EMBO J. 2001;20:6627–36.PubMedCrossRef
10.
Keane RW, Kraydieh S, Lotocki G, Alonso OF, Aldana P, Dietrich WD. Apoptotic and antiapoptotic mechanisms after traumatic brain injury. J Cereb Blood Flow Metab. 2001;21:1189–98.PubMedCrossRef
11.
Sugawara T, Noshita N, Lewen A, Gasche Y, Ferrand-Drake M, Fujimura M, et al. Overexpression of copper/zinc superoxide dismutase in transgenic rats protects vulnerable neurons against ischemic damage by blocking the mitochondrial pathway of caspase activation. J Neurosci. 2002;22:209–17.PubMed
12.
Saito A, Hayashi T, Okuno S, Ferrand-Drake M, Chan PH. Interaction between XIAP and SMAC/DIABLO in the mouse brain after transient focal cerebral ischemia. J Cereb Blood Flow Metab. 2003;23:1010–9.PubMedCrossRef
13.
Deveraux QL, Leo E, Stennicke HR, Welsh K, Salvesen GS, Reed JC. Cleavage of human inhibitor of apoptosis protein XIAP results in fragments with distinct specificities for caspases. EMBO J. 1999;18:5242–51.PubMedCrossRef
14.
Martins LM, Iaccarino I, Tenev T, Gschmeissner S, Totty NF, Lemoine NR, et al. The serine protease Omi/HtrA2 regulates apoptosis by binding XIAP through a reaper-like motif. J Biol Chem. 2002;277:439–44.PubMedCrossRef
15.
Duckett CS, Nava VE, Gedrich RW, Clem RJ, Van Dongen JL, Gilfillan MC, et al. A conserved family of cellular genes related to the baculovirus IAP gene and encoding apoptosis inhibitors. EMBO J. 1996;15:2685–94.PubMed
16.
Takahashi R, Deveraux Q, Tamm I, Welsh K, Assa-Munt N, Salvesen GS, et al. A single BIR domain of XIAP sufficient for inhibiting caspases. J Biol Chem. 1998;273:7787–90.PubMedCrossRef
17.
Srinivasula SM, Hegde R, Saleh A, Datta P, Shiozaki E, Chai J, et al. A conserved XIAP-interaction motif in caspase-9 and SMAC/DIABLO regulates caspase activity and apoptosis. Nature. 2001;410:112–6.PubMedCrossRef
18.
Salako SE. The declaration of Helsinki 2000: ethical principles and the dignity of difference. Med Law. 2006;25(2):341–54.PubMed
19.
Discovery Studio Gene v1.5 from Accelrys primer designing program, USA. 2007.
20.
Wobser H, Dorn C, Weiss TS, Amann T, Bollheimer C, Büttner R, Schölmerich J, Hellerbrand C. Lipid accumulation in hepatocytes induces fibrogenic activation of hepatic stellate cells. Cell Res. 2009;19:996–1005. doi:10.​1038/​cr.​2009.​73.PubMedCrossRef
21.
DeSantis C, Howlader N, Cronin KA, Jemal A. Breast cancer incidence rates in U.S. women are no longer declining. Cancer Epidemiol Biomarkers Prev. 2011;20(5):733–9.PubMedCrossRef
22.
Ijaduola TG, Smith EB. Pattern of breast cancer among white-American, African-American, and nonimmigrant west-African women. J Natl Med Assoc. 1998;90(9):547–51.PubMed
23.
Vorobiof DA, Sitas F, Vorobiof G. Breast cancer incidence in South Africa. J Clin Oncol. 2001;19(18):125S–7S.PubMed
24.
Reeves GK, Beral V, Green J, Gathani T, Bull D. Hormonal therapy for menopause and breast cancer risk by histological type: a cohort study and meta-analysis. Lancet Oncol. 2002;7:910–8.CrossRef
25.
Lambrechts S, Decloedt J, Neven P. Breast cancer prevention: lifestyle changes and chemoprevention. Acta Clin Belg. 2011;66(4):283–92.PubMed
26.
Freudenheim JL, Marshall JR, Vena JE. Lactation history and breast cancer risk. Am J Epidemiol. 1997;146:932–8.PubMedCrossRef
27.
Furberg H, Newman B, Moorman P, Millikan R. Lactation and breast cancer risk. Int J Epidemiol. 1999;28:396–402.PubMedCrossRef
28.
Zheng T, Holford TR, Mayne ST, Owens PH, Zhang Y, Zhang B, Boyle P, Zahm SH. Lactation and breast cancer risk: a case–control study in Connecticut. Br J Cancer. 2001;84(11):1472–6.PubMedCrossRef
29.
Marchbanks PA, McDonald JA, Wilson HG, Folger SG, Mandel MG, Daling JR, Bernstein L, Malone KE, Ursin G, Strom BL, Norman SA, Wingo PA, Burkman RT, Berlin JA, Simon MS, Spirtas R, Weiss LK. Oral contraceptives and the risk of breast cancer. N Engl J Med. 2002;346(26):2025–32.PubMedCrossRef
30.
Burkman R, Schlesselman JJ, Zieman M. Safety concerns and health benefits associated with oral contraception. Am J Obstet Gynecol. 2004;190(4):S5–22.PubMedCrossRef
31.
Monzo M, Rosell R, Felip E, Astudillo J, Sánchez JJ, Maestre J, Martín C, Font A, Barnadas A, Abad A. A novel anti-apoptosis gene: re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers. J Clin Oncol. 1999;17(7):2100–4.PubMed
32.
Ryan B, O’Donovan N, Browne B, O’Shea C, Crown J, Hill ADK, McDermott E, O’Higgins N, Duffy MJ. Expression of survivin and its splice variants survivin-2B and survivin-ΔEx3 in breast cancer, molecular diagnostics. Br J Cancer. 2004;92:120–4.CrossRef
33.
O`Driscoll L, Linhan R, Kennedybc M, Cronina D, Purcellbc R, Glynna S, McDermottd EW, Hilld AD, O’Higginsd NJ, Parkinsone M, Clynesa M. Lack of prognostic significance of survivin, survivin-ΔEx3, survivin-2B, galectin3, bag-1, bax-α and MRP-1 mRNAs in breast cancer. Cancer Lett. 2003;201:225–36.CrossRef
34.
Tanaka K, Iwamoto S, Gon G, Nohara T, Iwamoto M, Tanigawa N. Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res. 2000;6(1):127–34.PubMed
35.
Kennedy SM, O’Driscoll L, Purcell R, Fitz-Simons N, McDermott EW, Hill AD, O’Higgins NJ, Parkinson M, Linehan R, Clynes M. Prognostic importance of survivin in breast cancer. Br J Cancer. 2003;88:1077–83.PubMedCrossRef
36.
Riedl SJ, Renatus M, Schvanzenbacher R, Zhou Q, Sun C, Fesik SW, et al. Structural basis for the inhibition of caspase-3 by XIAP. Cell. 2001;104:791–800.PubMedCrossRef
37.
Srinivasula SM, Datta P, Fan XJ, Fernandes-Alnemri T, Huang Z, Alnemri ES. Molecular determinants of the caspase-promoting activity of SMAC/DIABLO and its role in the death receptor pathway. J Biol Chem. 2000;275:36152–7.PubMedCrossRef
38.
Huang Y, Park YC, Rich RL, Segal D, Myszak DG, Wu H. Structural basis of caspase inhibition by XIAP; differential role of linker versus the BIR domain. Cell. 2001;104:781–90.PubMed
39.
Kashkar H, Haefs C. XIAP-mediated caspase inhibition in Hodgkin’s lymphoma-derived B cells. J Exp Med. 2003;198:341–7.PubMedCrossRef
40.
Chauhan D, Li G, Hideshima T, Podar K, Mitsiades C, Mitsiades N, et al. JNK-dependent release of mitochondrial protein, SMAC, during apoptosis in multiple myeloma (MM) cells. J Biol Chem. 2003;278:17593–6.PubMedCrossRef
41.
Yoo NJ, Kim HS, Kim SY. Immunohistochemical analysis of SMAC/DIABLO expression in human carcinomas and sarcomas. APMIS. 2003;111:382–8.PubMedCrossRef
42.
Adida C, Berrebi D, Peuchmaur M, Reyes-Mugica M, Altieri DC. Anti-apoptosis gene, survivin, and prognosis of neuroblastoma. Lancet. 1998;351:882–3.PubMedCrossRef
43.
Ryan B, Konecny E, Kahlert S, Wang J, Untch M, Meng G, Pegram M, Podratz K, Crown J, Salmon D, Duffy M. Survivin expression in breast cancer predicts clinical outcome and is associated with HER2, VEGF, urokinase plasminogen activator and PAI-1. Ann Oncol. 2006;17:597–604.PubMedCrossRef
44.
Zhao JM, Zhu ZH, Wu QL, Hou JH, Huang XP, Zhang PY, Rong TH. Expression of Smac in stage I-II non-small cell lung cancer and its clinical significance. Ai Zheng. 2006;25(5):631–4.PubMed
45.
Lee CW, Raskett CM, Prudovsky I, Altieri DC. Molecular dependence of estrogen receptor—negative breast cancer on a notch-survivin signaling axis. Cancer Res. 2008;68(13):5273–81.PubMedCrossRef
46.
Xie W, Jiang P, Miao L, Zhao Y, Zhimin Z, Qing L, Zhu WG, Wu M. Proapoptotic SMAC/DIABLO is transcriptionally upregulated by E2F1. Nucleic Acids Res. 2006;34(7):2046–55.PubMedCrossRef
47.
Neubauer NL, Ward EC, Patel P, Lu Z, Lee I, Blok LJ, Hanifi-Moghaddam P, Schink J, Kim JJ. Progesterone receptor-B induction of BIRC3 protects endometrial cancer cells from AP1-59-mediated apoptosis. Horm Cancer. 2011;2(3):170–81. doi:10.​1007/​s12672-011-0065-7.PubMedCrossRef
48.
Scott JD, Gretch DR. Molecular diagnostics of hepatitis C virus infection: a systematic review. JAMA. 2007;297(7):724–32.PubMedCrossRef
49.
Sohn DM, Kim SY, Baek MJ, Lim CW, Lee MH, Cho MS, Kim TY. Expression of surviving and clinical correlation in patients with breast cancer. Biomed Pharmacother. 2006;60(6):289–92.PubMedCrossRef
Metadata
Title
Reciprocal expression of survivin and SMAC/DIABLO in primary breast cancer
Authors
A. Mansour
M. Nabil
R. Ali-Labib
H. Said
F. Annos
Publication date
01-12-2012
Publisher
Springer US
Published in
Medical Oncology / Issue 4/2012
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-011-0129-0

Other articles of this Issue 4/2012

Medical Oncology 4/2012 Go to the issue

Original Paper

MicroRNA-148a is silenced by hypermethylation and interacts with DNA methyltransferase 1 in gastric cancer

Original Paper

Is there association between handedness and radiosensitivity in breast cancer women?

Original Paper

Aberrant elevated microRNA-146a in dendritic cells (DC) induced by human pancreatic cancer cell line BxPC-3-conditioned medium inhibits DC maturation and activation

Case Report

Cutaneous blastic plasmacytoid dendritic cell neoplasm occurring after spontaneous remission of acute myeloid leukemia: a case report and review of literature

Original Paper

Single-nucleotide polymorphisms of integrins are associated with the risk and lymph node metastasis of oral squamous cell carcinoma

Original Paper

Progranulin overexpression predicts overall survival in patients with glioblastoma

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits